Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
about
In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.Facilitating Akt clearance via manipulation of Hsp70 activity and levels.Synergistic Apoptosis-Inducing Antileukemic Effects of Arsenic Trioxide and Mucuna macrocarpa Stem Extract in Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism.Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer CellsHsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsThe presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolismSynergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modelingInhibition of the heat shock response by PI103 enhances the cytotoxicity of arsenic trioxide.Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.Multimodal delivery of irinotecan from microparticles with two distinct compartmentsThe HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.
P2860
Q30665874-0F9941A5-0442-403F-84EA-3B9227405D8AQ33593935-7AFE0B6E-EA4F-4034-8FB9-581090A3D940Q35147292-D945EC7B-5E37-45ED-8133-D8B903356269Q35528633-5F75E457-7493-44C4-8CDB-9C2AD36A9165Q35686894-F5985DF1-3F5D-4E19-ACEA-FAB6A353A29BQ35823157-BD9D8CF3-D741-4D4B-BEDF-4E765FBF2F51Q36326369-0D3126F9-4F80-4031-BBAC-5A685E6BF423Q37275674-B2310EE0-8044-4E5B-956F-28363D97093DQ38326197-7B70B094-C851-49FE-BB68-96762973C00AQ38903506-FFD00256-749E-4F72-84F5-2B3EB1537BDDQ39431815-478AF8DE-428F-4E95-BA62-45644CA5A4F9Q40069992-B42B767F-6F9D-49F2-836C-3C836C4EBD1CQ41335784-DF437DE2-0D79-425B-9592-130AAAFADF02Q53347165-E1D2D79D-714E-4D6C-8388-F9F7DE9648AD
P2860
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@en
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@nl
type
label
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@en
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@nl
prefLabel
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@en
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@nl
P2093
P2860
P356
P1433
P1476
Targeting Hsp90 by 17-AAG in l ...... th arsenic trioxide and Ara-C.
@en
P2093
Andreeff M
Keating MJ
McQueen TJ
Pelicano H
Plunkett W
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404140
P577
2006-04-01T00:00:00Z